Asset Scouting Services

We support a number of companies in their in-licensing activities, helping them develop strategies to leverage their strengths and achieve their corporate objectives. We also provide ongoing scouting support, working alongside the client’s internal efforts to generate a flow of new opportunities. Such activities include:

  • working with the client’s global scouting team to identify companies and assets not yet appearing in industry pipeline databases
  • contacting companies that fit our client’s criteria to ascertain their interest in a partnership
  • targeted and regular attendance at partnering and scientific conferences
  • scanning of new and recent literature to identify emerging opportunities
  • outreach and networking with tech transfer offices, our industry contacts and licensing professionals

Our recent work has included supporting the Search & Evaluation team at a big pharma company to identify new opportunities in immune-oncology, orphan diseases, immunology, cardiovascular and fibrosis. We were also engaged by an emerging company backed by Versant Ventures and Celgene, for whom we conducted an extensive global search for first-in-class antibodies over a 12 month+ period. Many of our scouting relationships are ongoing and are all non-exclusive.

Looking to partner or out-license your assets?

Alacrita supports many biotech and pharmaceutical companies in their asset scouting efforts. Submit your assets and let us help you build a successful partnership.

Submit Assets

Featured Case Study: Pharma scouting for new antibody therapeutics


A well-capitalized biotech company focused on developing antibody therapeutics for cancer and fibrosis needed to find new preclinical assets to in-license, with a particular focus on immune-oncology. A far-reaching search would be required to find the right match.


Over the course of two years, we conducted a systematic, global pharma scouting project through channels that included scientific literature, databases of grants and patents; tech transfer offices and scientific societies.

We used several industry pipeline databases to identify and contact academics, biotech startups and existing companies with novel or fast-follower preclinical stage antibodies.

In addition to desk research, we attended numerous local and international networking and biotech partnering events to scout for opportunities on behalf of the client.

Having exhausted opportunities which had been published, we then wanted to find assets that were not yet in the public domain. We launched a scientific outreach campaign, sending individual, personalized emails to over 35,000 cancer researchers around the world.

We also deployed artificial intelligence and machine learning to scour and monitor the scientific literature to find scientific papers that described assets that fit our client’s criteria.

Our search and outreach identified several new in-licensing opportunities for our client, which are currently under due diligence or deal term negotiation.